February 22, 2021

Novavax Completes Enrolling 30,000 People In U.S. Trial Of COVID-19 Vaccine-Reuters

Drug developer Novavax Inc said on Monday it has completed enrolling 30,000 volunteers in a late-stage study of its COVID-19 vaccine in the United States and Mexico. The company said last month its vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective against the more highly contagious variant first discovered in the UK. Reuters, 02/22/2021